Evidence map›Paper›PMID 26600112›Full record

ReviewThe Psychiatric clinics of North America2015

New Developments in Insomnia Medications of Relevance to Mental Health Disorders.

Andrew D Krystal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Psychiatric clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020
    Trial
  2. Cells · 2025
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andrew D KrystalDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27705, USA. Electronic address: andrew.krystal@duke.edu.

Funding

Behavioral Insomnia Therapy for those with Insomnia and DepressionR01MH076856 · NIMH · TORONTO METROPOLITAN UNIVERSITY · PI CARNEY, COLLEEN E · 2008 to 2012
$1.7M
Biomarkers of the Response to CBT for Insomnia in Major DepressionR01HL096492 · NHLBI · DUKE UNIVERSITY · PI KRYSTAL, ANDREW D · 2009 to 2012
$1.6M
2/3-Improving Depression Outcome by Adding CBT for Insomnia to AntidepressantsR01MH078961 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUYSSE, DANIEL J. · 2008 to 2012
$1.3M
3/3-Improving Depression Outcome by Adding CBT for Insomnia to AntidepressantsR01MH079256 · NIMH · DUKE UNIVERSITY · PI KRYSTAL, ANDREW D · 2008 to 2012
$1.1M
2/3-Reducing Suicide Ideation Through Insomnia Treatment (REST-IT)R01MH095780 · NIMH · DUKE UNIVERSITY · PI KRYSTAL, ANDREW D · 2012 to 2016
$904k
2/2-Sequenced Therapies for Comorbid and Primary InsomniasR01MH091053 · NIMH · LAVAL UNIVERSITY · PI MORIN, CHARLES M. · 2011 to 2015
$882k
NHLBI NIH HHS R01 HL096492NHLBI NIH HHS R01HL096492NIMH NIH HHS R01 MH076856NIMH NIH HHS R01 MH078961NIMH NIH HHS R01 MH079256NIMH NIH HHS R01 MH091053NIMH NIH HHS R01 MH095780
6 · The paper itself

Abstract

Many insomnia medications with high specificity have become available recently. They provide a window into the clinical effects of modulating specific brain systems and establish a new guiding principal for conceptualizing insomnia medications: "mechanism matters." A new paradigm for insomnia therapy in which specific drugs are selected to target the specific type of sleep difficulty for each patient includes administering specific treatments for patients with insomnia comorbid with particular psychiatric disorders. This article reviews insomnia medications and discusses the implications for optimizing the treatment of insomnia occurring comorbid with psychiatric conditions.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesHistamine AntagonistsHumansMental DisordersOrexin Receptor AntagonistsReceptors, MelatoninSleep Initiation and Maintenance DisordersAdrenergic alpha-1 Receptor AntagonistsAntidepressive AgentsAntipsychotic AgentsBenzodiazepinesHistamine AntagonistsOrexin Receptor AntagonistsReceptors, MelatoninComorbid psychiatric disordersDoxepinEszopicloneInsomniaPersonalizationPrazosinSuvorexant

Identifiers

PMID26600112
PMCPMC5972036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.